Norway, May 18 -- Circio Holding ASA, a biotechnology company developing novel circular RNA expression technology for gene and cell therapy, today publishes the poster and slides that were presented at the American Society of Gene and Cell Therapy Annual Meeting in Boston.In the oral presentation, Circio s CEO Dr. Erik D Wiklund provided an overview and the latest developments of the circVec circular RNA-based gene expression platform. The superior stability of circular RNA enables enhanced and prolonged gene expression and can be deployed to enable more potent and safer gene and cell therapies. In the context of AAV gene therapy, circVec yields up to 40 and 50-fold increased gene expression in heart and eye, respectively. High dosing requi...